Growth Hormone Secretagogues and IGF-1 Analogs Growth hormone secretagogues, including CJC-1295, ipamorelin, and sermorelin, and IGF-1 analogs are increasingly used in wellness and optimization settings and are frequently co-administered with BPC-157 or TB-500 (Rahman et al
Preclinical and clinical studies demonstrate that co-administration of these peptides achieves superior reductions in bodyweight, appetite, and fasting glucose than either agent aloneachieving up to a 17% reduction in bodyweight in non-diabetic individuals and a 15.6% reduction in patients with type 2 diabetes over 2032 weeks
While research is ongoing and treatment recommendations are individualized, BPC-157 is frequently discussed in relation to: Every patient is different
Future clinical trials and translational studies are required to better evaluate these interventions and establish comprehensive treatment protocols for METH users
Patients exploring broader peptide therapy protocols often find that epithalon is considered alongside other bioregulators depending on individual health goals and lab markers
